Clinical trials combine intra-tumor injection of IFN-α with anti-PD-1 immunotherapy (Clinicaltrials.gov study identifier: NCT02339324), to overcome PD-L1-mediated escape [274]. The gene discussed is CD274; the disease is neoplasm.